Linezolid

Linezolid

SCHEMBL2322867

CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1.NCC(=O)O

nearest known ligand 0.89

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Linezolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAOB P27338 11/20 0.89
MAOA P21397 6/20 0.89
PTGS1 P23219 2/20 0.89
SDHA P31040 2/20 0.89
LMNA P02545 1/20 0.89
CALML3 P27482 1/20 0.89
F10 P00742 4/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Linezolid SCHEMBL5524444 0.94 MAOB (1.00) MAOBMAOAPTGS1SDHALMNA
Linezolid SCHEMBL2222512 0.94 MAOB (1.00) MAOBMAOAPTGS1SDHALMNA
Linezolid SCHEMBL7992562 0.94 MAOB (1.00) MAOBMAOAPTGS1SDHALMNA
Linezolid SCHEMBL30226927 0.94 MAOB (1.00) MAOBMAOAPTGS1SDHALMNA
Linezolid SCHEMBL30638355 0.94 MAOB (1.00) MAOBMAOAPTGS1SDHALMNA
Linezolid SCHEMBL374752 0.94 MAOB (1.00) MAOBMAOAPTGS1SDHALMNA
Linezolid SCHEMBL1561095 0.94 MAOB (1.00) MAOBMAOAPTGS1SDHALMNA
Linezolid SCHEMBL5027 0.94 MAOB (1.00) MAOBMAOAPTGS1SDHALMNA
Linezolid SCHEMBL17964217 0.94 MAOB (0.94) MAOBMAOAPTGS1SDHALMNA
Linezolid SCHEMBL8214142 0.94 MAOB (0.98) MAOBMAOAPTGS1SDHALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3362071-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY Grünenthal GmbH (DE) 2018-08-22 EP disclosed
WO-2017049294-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY THAR PHARMACEUTICALS, INC. (US) 2017-03-23 WO disclosed
WO-2011097269-A9 CRYSTALLIZATION METHOD AND BIOAVAILABILITY THAR PHARMACEUTICALS, INC. (US) 2012-12-27 WO disclosed
EP-2531200-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY Thar Pharmaceuticals, Inc. (US) 2012-12-12 EP disclosed
WO-2011097269-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY THAR PHARMACEUTICALS, INC. (US) 2011-08-11 WO disclosed